Severe neonatal multiple sulfatase deficiency presenting with hydrops fetalis in a preterm birth patient

Lars Schlotawa1 | Thomas Dierks2 | Sophie Christoph3 | Eva Cloppenburg4 | Andreas Ohlenbusch1 | G. Christoph Korenke3 | Jutta Gärtner1

1Department of Paediatrics and Adolescent Medicine, University Medical Center Göttingen, Göttingen, Germany
2Department of Chemistry, Biochemistry I, Bielefeld University, Bielefeld, Germany
3Department of Child Neurology and Metabolic Disorders, Medical Centre Oldenburg, University Children's Hospital Oldenburg, Oldenburg, Germany
4Department of Neonatology, Intensive Care Medicine and Paediatric Cardiology, Medical Centre Oldenburg, University Children's Hospital Oldenburg, Oldenburg, Germany

Correspondence
Lars Schlotawa, Department of Paediatrics and Adolescent Medicine, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
Email: lars.schlotawa@med.uni-goettingen.de

Communicating Editor: Jaak Jaeken

Funding information
Deutsche Forschungsgemeinschaft, Grant/ Award Number: DFG Ga354/14-1; Department of Paediatrics and Adolescent Medicine, University Medical Center Göttingen, Germany

1 INTRODUCTION

Multiple sulfatase deficiency (MSD, MIM #272200) is a rare lysosomal storage disorder (LSD) caused by the combined deficiency of cellular sulfatases resulting in a complex LSD. Clinical features comprise variable signs of developmental delay followed by progressive loss of motor and cognitive function, dysmorphism, organomegaly and an ichthyotic skin rash.1 MSD is caused by mutations in the sulfatase modifying factor 1 gene (SUMF1) resulting in misfolding and early degradation of catalytically impaired formylglycine generating enzyme (FGE).2 FGE activates newly synthesized sulfatases through the oxidation of a conserved cysteine to formylglycine, which is the essential catalytic residue of every sulfatase (17 nonredundant enzymes in

Abbreviations: FGE, formylglycine generating enzyme; LSD, lysosomal storage disorder; MSD, multiple sulfatase deficiency; NIHF, nonimmunological hydrops fetalis; NVS, neonatal very severe MSD; SNP, single nucleotide polymorphism; SUMF1, sulfatase modifying factor 1.
humans). FGE malfunctioning results in absent or reduced sulfatase activities in different cellular compartments causing the unique combination of clinical features from single sulfatase deficiencies in MSD. More than 50 different SUMF1 mutations have been described, most of them missense mutations. Different forms of MSD can be distinguished based on time of onset and clinical severity that are determined by residual functionality of FGE variants. Mutations generating less severe FGE dysfunction were found in attenuated cases, whereas deletions, frameshift, or early stop mutations result in complete protein loss and severe forms of MSD (neonatal very severe MSD, NVS). Only few of such NVS patients have been published before.

Hydrops fetalis is a severe pregnancy condition. Whereas immunological hydrops fetalis caused by fetal anemia due to rhesus incompatibility has historically been the most frequent cause, nonimmunological disorders cause more than 85% of hydrops fetalis nowadays with an incidence of 1 in 2000-3000 pregnancies. Actual cases result from infectious diseases, congenital heart defects, feto-fetal transfusion, and genetic diseases. Inborn errors of metabolism are rare causes of non-immunological hydrops fetalis (NIHF), with LSDs being more common than others. NIHF is a symptom in about 14 different LSDs. While various pathophysiological processes have been discussed to favor NIHF, the genuine pathophysiology remains unknown.

Here we describe pathological findings in a preterm neonate presenting with a hydrops fetalis as leading symptom in a neonatal very severe and rarely seen form of MSD.

2 | MATERIALS AND METHODS

Cell culture, DNA, RNA, protein extraction, sequencing of the SUMF1 gene, sulfatase activity assays, and FGE western blot was performed as described before. We used a polyclonal rabbit anti-transferrin antibody, concentration 1:10 000 in PBS/5% nonfat dried milk, as loading control (DakoCytomation, Glostrup, Denmark, Cat. No. A0061).

3 | PATIENT REPORT

The male patient is the third child of a nonconsanguineous German couple. Birth weight 2000 g (71st centile), length 40 cm (19th centile), and head circumference 31 cm (67th centile). The mother had a history of two previous miscarriages and two elder siblings are healthy. From 19 weeks of gestation, scans showed a significant ascites in the fetus. The baby was born at 31 + 5 weeks via caesarean section after premature rupture of membranes.

The patient showed a flattened nose, epicanthal folds, short limbs, a small chest, and a wide abdomen. The postnatal abdominal ultrasound showed a massive ascites that required drainage. A persistent fetal circulation was detected as well as reduced right and left ventricular output. Chest X-ray revealed respiratory distress syndrome and bilateral lung hypoplasia. Dilated cerebral ventricles were seen on cranial ultrasound scan. Excess excretion of chondroitin sulfate and dermatan sulfate was present in urine samples.

The patient required intubation followed by continuous ventilation starting directly after birth. Blood circulation and low blood pressure required immediate therapy with inotropes. An intraventricular hemorrhage was noted on day 3 complicated by an intraparenchymal bleeding and signs of intracranial pressure. The patient died on day 6 because of multi-organ failure.

4 | RESULTS

The activities of four different lysosomal sulfatases and nonlysosomal steroidsulfatase were absent or drastically reduced in patient's fibroblasts. Other lysosomal hydro- lases showed normal activities (Table 1). Sequencing of SUMF1 revealed a homozygous mutation c.191C>A creating a TAG stop codon at position 64 (p.Ser64Ter) in the FGE amino acid sequence. Both parents were heterozygous for the mutation. SUMF1 mRNA was fully transcribed in patient fibroblasts, although at reduced levels.

| Enzyme                          | Activity (nmol/h per mg) | Reference range (nmol/h per mg) |
|--------------------------------|--------------------------|--------------------------------|
| Arylsulfatase A                | 9                        | 387-1093                        |
| Arylsulfatase B                | 0                        | 177-547                         |
| Steroidsulfatase               | 1a                       | 55-127a                         |
| Iduronate-2-sulfatase          | 0                        | 3-20                            |
| N-Acetylgalactosamine-6-sulfatase | 0                   | 6-9                             |
| α-L-Iduronidase                | 181                      | 34-139                          |
| β-Hexosaminidase A + B         | 8375                     | 1806-12 942                     |

*(pmol/h per mg).*
In addition, child and parents carried the previously reported benign sequence variant c.188G>A, p.Ser63Asn (Figure 1).

No FGE was detected by western blot analysis in lysates of patient's fibroblasts. Fibroblast lysates from two other neonatal very severe MSD cases served as controls and did not show detectable FGE expression, whereas FGE was clearly detectable in lysates of non-MSD fibroblasts (Figure 2).

**FIGURE 1** Molecular analysis of *SUMF1*. Sequences of the *SUMF1* gene in genomic DNA of the patient and both parents, and in mRNA of the patient isolated from patient fibroblasts. The analysis showed a homozygous mutation c.191C>A, p.Ser64Ter on gDNA and mRNA levels for the patient and the same mutation in heterozygosity in the parents. In addition, the patients' gDNA and mRNA carried the described SNP c.188G>A, p.Ser63Asn that was found in heterozygosity in the parents' gDNA.

In addition, child and parents carried the previously reported benign sequence variant c.188G>A, p.Ser63Asn (Figure 1).

The dysmorphic features in the patient and increased urinary GAG excretion were suspicious for a mucopolysaccharidosis. LSDs, including different forms of mucopolysaccharidosis, are a rare cause of NIHF and MSD is one of the rarest entities.1,15 The majority of MSD cases are of the late infantile type, only few neonatal cases have been described. Some patients presented with hydrops fetalis but all shared an eventful neonatal period with great likelihood of early death. All affected MSD newborns had symptoms in common that resemble mucopolysaccharidosis such as coarse facial appearance, corneal clouding, hydrocephalus and skeletal changes. Ichthyotic skin rash, one of the leading clinical sign in MSD with later onset, is not regularly detected in neonatal cases.2,6-10 A predominantly neurological deterioration and developmental delay or absent psychomotor development appears only in MSD cases with later onset.1,18

This report describes the earliest onset of MSD to date. Dysmorphic features and hydrops fetalis, present since the 19th week of gestation, seem to be the earliest clinical signs in neonatal MSD. The cardiac problems as well as the lung hypoplasia are likely an effect of hydrops fetalis but cannot be excluded as a genuine symptom of MSD.

Sulfatase activities in the patient were absent or below the detection limit (Table 1). Complete absence of sulfatase activities in MSD is considered to cause the severest MSD phenotype.2 In all NVS cases described so far residual sulfatase activities were either absent or extremely reduced like in our patient. This is supposed to result from absent FGE activity caused by a complete loss of function due to nonsense mutations or severe missense mutations.2,6-10 Of note, also the *Sumf1* gene-trap MSD mouse model showed absent sulfatase activities in all tested tissues and displayed a severe
phenotype with early lethality, growth retardation, bone changes and dysmorphic features. On the other hand, hypomorph SUMF1 variants represent the majority of mutations found in MSD. They destabilize FGE but allow for some residual activity. In line with this, sulfatases also show residual activities and such MSD patients present with late infantile or juvenile MSD types.

The homozygous mutation detected in the present patient results in a complete loss of FGE function. No FGE protein could be detected in lysates from patient fibroblasts. Endogenous mRNA was detectable, but only at low amounts likely as a result of nonsense mediated decay. Due to homozgyosity, all clinical findings in our patient are a direct result of a single mutation. The SUMF1 c.191C>A, p.Ser64Ter mutation is one of the most deleterious in MSD. The same mutation was published in compound heterozygosity in combination with an undescribed missense mutation in a patient that displayed neonatal dysmorphic features but appeared to be less severely affected than our patient and other NVS MSD cases. This is most likely a result of residual FGE activity of the second, putative hypomorph mutation in this child and less likely the influence of yet unknown disease modifiers in MSD. A genotype-phenotype correlation in NVS MSD cases based on different SUMF1 nonsense mutations remains speculative until more cases with a defined genotype will be described.

Until today, MSD is untreatable. We strongly recommend considering hydrops fetalis as an early clinical sign of LSDs and MSD. Enzymatic and genetic testing for this group of diseases with special emphasis on sulfatase function should be part of a routine diagnostic set up after the detection of hydrops fetalis in the unborn or newborn child.

ACKNOWLEDGMENTS

We would like to thank the patient’s family for agreeing on publishing the data. We would like to thank Tanja Wilke for excellent technical assistance, Dr. Janine Woellner for carefully proofreading the manuscript, and Dr. Karthikeyan Radhakrishnan for helpful discussions.

CONFLICT OF INTEREST

Lars Schlotawa, Thomas Dierks, Sophie Christoph, Eva Cloppenburg, Andreas Ohlenbusch, Korenke Cristoph, and Jutta Gärtner declare no conflict of interest.

INFORMED CONSENT

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000(5). Additional informed consent was obtained from the patients parents for being included in this case report.

ORCID

Lars Schlotawa https://orcid.org/0000-0002-7415-4905

REFERENCES

1. Ahrens-Nicklas R, Schlotawa L, Ballabio A, et al. Complex care of individuals with multiple sulfatase deficiency: clinical cases and consensus statement. Mol Genet Metab. 2018;123:337-346.
2. Schlotawa L, Ennemann EC, Radhakrishnan K, et al. SUMF1 mutations affecting stability and activity of formylglycine generating enzyme predict clinical outcome in multiple sulfatase deficiency. Eur J Hum Genet. 2011;19:253-261.
3. Cosma MP, Pepe S, Annunziata I, et al. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell. 2003;113:445-456.
4. Dierks T, Schmidt B, Borisosenko LV, et al. Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C(alpha)-formylglycine generating enzyme. Cell. 2003;113:435-444.
5. Annunziata I, Bouche V, Lombardi A, Settembre C, Ballabio A. Multiple sulfatase deficiency is due to hypomorphic mutations of the SUMF1 gene. Hum Mutat. 2007;28:928.
6. Burch M, Fensom AH, Jackson M, Pitts-Tucker T, Congdon PJ. Multiple sulphatase deficiency presenting at birth. Clin Genet. 1986;30:409-415.
7. Busche A, Hennermann JB, Burger F, et al. Neonatal manifestation of multiple sulfatase deficiency. Eur J Pediatr. 2009;168:969-973.
8. Garavelli L, Santoro L, Iori A, et al. Multiple sulfatase deficiency with neonatal manifestation. Ital J Pediatr. 2014;40:86.
9. Nur BG, Mihci E, Pepe S, et al. Neonatal multiple sulfatase deficiency with a novel mutation and review of the literature. Turk J Pediatr. 2014;56:418-422.
10. Perlmutter-Cremer N, Libert J, Vamos E, Spehl M, Liebaers I. Unusual early manifestation of multiple sulfatase deficiency. Ann Radiol. 1981;24:43-48.
11. Bellini C, Donarini G, Paladini D, et al. Etiology of non-immune hydrops fetalis: an update. Am J Med Genet A. 2015;167A:1082-1088.
12. Sohan K, Carroll SG, De La Fuente S, Soothill P, Kyle P. Analysis of outcome in hydrops fetalis in relation to gestational age at diagnosis, cause and treatment. Acta Obstet Gynecol Scand. 2001;80:726-730.
13. Takci S, Gharibzadeh M, Yurdakok M, et al. Etiology and outcome of hydrops fetalis: report of 62 cases. Pediatr Neonatol. 2014;55:108-113.
14. Burin MG, Scholz AP, Gus R, et al. Investigation of lysosomal storage diseases in nonimmune hydrops fetalis. Prenat Diagn. 2004;24:653-657.
15. Whybra C, Mengel E, Russo A, et al. Lysosomal storage disorder in non-immunological hydrops fetalis (NIHF): more common than assumed? Report of four cases with transient NIHF and a review of the literature. Orphanet J Rare Dis. 2012;7:86.
16. Hutchison AA, Drew JH, Yu VY, Williams ML, Fortune DW, Beischer NA. Nonimmunologic hydrops fetalis: a review of 61 cases. Obstet Gynecol. 1982;59:347-352.
17. Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. *Pediatrics*. 2009;123:1191-1207.

18. Sabourdy F, Mourey L, Le Trionnaire E, et al. Natural disease history and characterisation of SUMF1 molecular defects in ten unrelated patients with multiple sulfatase deficiency. *Orphanet J Rare Dis*. 2015;10:31.

19. Settembre C, Annunziata I, Spampanato C, et al. Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. *Proc Natl Acad Sci U S A*. 2007;104:4506-4511.

20. Gort L, Granell MR, Fernandez G, Carreto P, Sanchez A, Coll MJ. Fast protocol for the diagnosis of lysosomal diseases in nonimmune hydrops fetalis. *Prenat Diagn*. 2012;32:1139-1142.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of this article.

**Figure S1** Original file of the FGE expression Western blot used for Figure .

**How to cite this article:** Schlotawa L, Dierks T, Christoph S, et al. Severe neonatal multiple sulfatase deficiency presenting with hydrops fetalis in a preterm birth patient. *JIMD Reports*. 2019;49:48–52. [https://doi.org/10.1002/jmd2.12074](https://doi.org/10.1002/jmd2.12074)